The European Union may pass a law that prohibits the import of medicines derived from sheep, goats and cattle, according to Jeffrey Trewhitt, vice president of communications for the Pharmaceutical Research and Manufacturers of America, Washington.
The European Union may pass a law that prohibits the import of medicines derived from sheep, goats and cattle, according to Jeffrey Trewhitt, vice president of communications for the Pharmaceutical Research and Manufacturers of America, Washington.
The ban, proposed because of concerns about Bovine Spongiform Encephalopathy, also known as Creutzfeldt-Jakob disease or mad cow disease, would affect roughly 85% of products exported to Europe by pharmaceutical companies in the United States. The potential economic impact of the ban is $4.5 billion in sales.
"This would affect any product that contained gelatin," Trewhitt explained. Gelatin, a common ingredient in drugs, is composed of the boiled skin, connective tissue and bones of animals, including those included in the proposed ban.
The European Union is the United States largest economic partner, largest investment partner and second-largest trading partner. Total U.S.-European Union trade was $270 billion in 1996. The two-way trade supports about six million jobs on both sides of the Atlantic.
European Union legislators originally planned to implement the prohibition on Jan. 1, but have postponed the date to April 1 in order to more closely analyze the risk posed by the products.
Risk analysis by PhRMA showed that the risk of acquiring mad cow disease by taking three gelatin capsules every day for one year was one in 100 billion.
The Clinton Administration is concerned about the proposal. American emissaries, representing national trade and commerce departments, were scheduling discussions with legislators in major European cities at press time. They will be discussing alternatives to the blanket ban, such as delegating the choice of embargoing certain products to individual member countries, or prohibiting only specific, high-risk drugs. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.